DNA damage in rapidly dividing cells

"DNA damage in rapidly dividing cells" is not a specific molecule, protein, or canonical therapeutic target. Rather, it describes a **cellular process** or state—namely, the occurrence of DNA lesions during frequent cell division. Rapidly dividing cells are particularly vulnerable to accumulating DNA damage due to increased replication stress and exposure to genotoxic agents[4][5][7]. This vulnerability is exploited by many cancer therapies that induce DNA damage preferentially in fast-dividing tumor cells[4][5][7]. Cells have evolved complex **DNA repair mechanisms**—including nucleotide excision repair, base excision repair, non-homologous end joining, and homologous recombination—to detect and correct such lesions[1][2][4]. Key proteins involved include ATM/ATR kinases, p53 tumor suppressor protein, PARP1 polymerase, 53BP1 nuclear bodies, RAD52 enzyme among others[1][3][4]. When these systems fail or are overwhelmed by excessive damage—as can happen in cancer or with certain chemotherapies—cells may undergo apoptosis or senescence to prevent propagation of mutations[2][3]. In oncology drug development and clinical practice, * The **therapeutic targets** are typically the enzymes/proteins involved in recognizing and repairing DNA damage (e.g., PARP1 inhibitors), not "DNA damage" itself. * Drugs like platinum compounds (cisplatin), alkylating agents (temozolomide), topoisomerase inhibitors (etoposide), and PARP inhibitors exploit this vulnerability by inducing irreparable DNA lesions specifically toxic to rapidly proliferating cancer cells[7]. * Biomarkers used clinically relate to deficiencies in specific repair pathways rather than the presence of generic "DNA damage." Because "DNA damage in rapidly dividing cells" does not refer to a single molecular entity but rather a biological phenomenon/process involving multiple pathways and proteins, **it is not considered a canonical therapeutic target**, nor does it have standard aliases or abbreviations. For structured data purposes this entry should be flagged as incorrect/incomplete as a molecular target. If you need information on specific molecules within this process—such as "Poly(ADP-ribose) polymerase 1," "Ataxia-telangiectasia mutated kinase," or others involved directly in sensing/repairing DNA breaks—please specify so structured information can be provided at the appropriate level of detail. > “Cancer cells divide rapidly and experience a high load of DNA damage—without efficient repair systems these cells will die. Accordingly cancer therapies often aim at overwhelming these systems” [5]. > > “The underlying mechanism for synergy [in combination therapy] is that the rapidly dividing cancer cells are more likely to be affected by DNA-damaging agents” [7].